Stocks · News reference

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

Sep 8, 2026, 12:17 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 8, 2026, 12:17 PM
Checked: Sep 8, 2026, 12:17 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 8, 2026, 2:29 PMBenzinga Newsdesk
GRI Bio shares are trading lower after the company announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 in patients with idiopathic pulmonary fibrosis.
GRI
SEC EDGARSep 8, 2026, 12:16 PMSEC EDGAR
8-K filing — GRI Bio, Inc. (GRI)
Filed: 2026-09-08 AccNo: 0001824293-26-000057 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
GRI
BenzingaAug 24, 2026, 2:36 PMBenzinga Newsdesk
GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.
GRI